Blockchain Registration Transaction Record

GeoVax Advances GEO-MVA Pivotal Study and Reports Q2 2026 Results

GeoVax Labs reports Q2 2026 financial results and advances GEO-MVA pivotal immunobridging study for mpox/smallpox vaccine. Also progressing Gedeptin immuno-oncology program. Learn more.

This news matters because GeoVax's progress on the GEO-MVA vaccine could help address the critical shortage of diversified MVA vaccine supply for mpox and smallpox, impacting global public health preparedness and biodefense. The advancement of Gedeptin also holds promise for improving cancer immunotherapy outcomes, potentially benefiting patients with solid tumors who do not respond to current treatments. For investors, the company's disciplined capital allocation and focus on programs with clear regulatory pathways signal potential value creation.